Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery, clinical development and commercialization of small molecule drugs that address medical needs mainly in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. Co.'s product candidate, CAPLYTA (lumateperone) has been approved for the treatment of schizophrenia in adults. Co. is developing ITI-1284, an oral disintegrating tablet for sublingual administration for the treatment of behavioral disturbances in patients with dementia and dementia-related psychosis and for the treatment of certain depressive disorders in the elderly.
ITCI SEC Filing Email Alerts Service
ITCI SEC Filing Email Alerts Service
|
Free ITCI Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.60 out of 4) 62nd percentile
(ranked higher than approx. 62% of all stocks covered)
Analysts' Target Price: ITCI Stock Forecast Based on Zacks ABR data; powered by Xignite |